Richard Nolan Townsend - May 13, 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
May 13, 2024
Transactions value $
-$66,093
Form type
4
Date filed
5/14/2024, 04:04 PM
Previous filing
Jan 9, 2024
Next filing
Jun 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Options Exercise $11.7K +5K +2.93% $2.33* 176K May 13, 2024 Direct F1
transaction LXEO Common Stock Sale -$66.1K -5K -2.85% $13.22 171K May 13, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (Right to Buy) Options Exercise -$11.7K -5K -3.25% $2.33* 149K May 13, 2024 Common Stock 5K $2.33 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $12.98 to $13.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F4 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.